The Effect of PRRT on Health-Related Quality of Life in NET Patients: A Prospective Study

#1825

Introduction: Neuroendocrine tumour (NET) patients experience poor health-related quality of life (HRQOL). Peptide receptor radionuclide therapy (PRRT) is a promising treatment option although its impact on HRQOL is not well understood.

Aim(s): This prospective observational study examined the time course of HRQOL in a cohort of patients at the Department of Nuclear Medicine The Queen Elizabeth Hospital, Adelaide.

Materials and methods: Patients received up to 4 Lutate inductions at 6-8-weekly intervals. The EORTC QLQ-C30 was administered prospectively at baseline and before each cycle. Mixed models for repeated measures examined relationships between time and HRQOL.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Patel D, Corsini N, Lawrie J, Nicholls D, Imogen R,

Keywords: PRRT, quality of life , Lutate,